Metabolomic Biomarkers for Colorectal Cancer

Simple item page
atmire.migration.oldid4525
dc.contributor.advisorBathe, Oliver F.
dc.contributor.authorFarshidfar, Farshad
dc.contributor.committeememberVogel, Hans J
dc.contributor.committeememberKopciuk, Karen A
dc.contributor.committeememberHilsden, Robert
dc.contributor.committeememberBuie, W. Donald
dc.date.accessioned2016-07-05T17:14:32Z
dc.date.available2016-07-05T17:14:32Z
dc.date.issued2016
dc.date.submitted2016en
dc.description.abstractColorectal cancer (CRC) is the second most common cancer in the North America. It is also a huge burden for society. Remarkable efforts have been and are being made to improve CRC diagnosis, to enhance the effectiveness of treatments, and to eventually improve the outcome of these patients. Metabolomic profiling, as a method for describing metabolic state and alterations in the molecular constituents and capable of yielding unique and invaluable information about tumor biology, has been employed. Using a range of spectroscopy and mass spectrometry techniques, we have sought to characterize the changes in the serum metabolome that appear as a result of malignant and pre-malignant lesions in the colon and rectum. In Chapter 2, Application of gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance (NMR) spectroscopy for staging CRC is described. Chapter 3 describes a larger study of 320 CRC and 31 colorectal adenoma cases as well as their matching controls by GC-MS, which led to the identification of validated metabolomic signature for identification of CRC and a proposed signature for identification of colorectal adenoma. In chapter 4, an effort for quantitative profiling of 62 CRC cases and 31 colorectal adenomas and their matching controls by tandem mass spectrometry is illustrated, and a validated quantitative signature for diagnosis of CRC is reported. Chapter 5 is dedicated to studying the prognostic value of metabolomic profiling in colorectal liver metastatic patients, and a novel workflow for estimation of recurrence risk using high-dimensional data is proposed. Challenges and pitfalls confronted in different steps of the project were addressed when possible by the use of available methods. Where no reliable method was available, we made an effort to develop one. This thesis, therefore, is focused on the metabolomic characterization of CRC and the adaptation of this knowledge for the development of clinically valuable biomarkers.en_US
dc.identifier.citationFarshidfar, F. (2016). Metabolomic Biomarkers for Colorectal Cancer (Doctoral thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/26885en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/26885
dc.identifier.urihttp://hdl.handle.net/11023/3101
dc.language.isoeng
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectBiostatistics
dc.subjectBiology--Molecular
dc.subjectOncology
dc.subjectBiochemistry
dc.subject.classificationCancer biomarkeren_US
dc.subject.classificationColorectal Canceren_US
dc.subject.classificationMetabolomicsen_US
dc.subject.classificationPrognosisen_US
dc.subject.classificationdiagnosisen_US
dc.subject.classificationStagingen_US
dc.subject.classificationMass spectrometryen_US
dc.titleMetabolomic Biomarkers for Colorectal Cancer
dc.typedoctoral thesis
thesis.degree.disciplineMedical Science
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameDoctor of Philosophy (PhD)
ucalgary.item.requestcopytrue
Files
Collections
Open Theses and Dissertations